Alipay Sees Tap! Users Pass 100 Million, Accelerating Payment and AI Innovations
Alipay Tap!, a QR code-based contactless payment and customer engagement solution introduced by Alipay in China in June 2024, reports today it has won over 100 million users within 11 months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424690776/en/
FamilyMart leverages Alipay Tap! to simplify payments and membership management.
Alipay Tap! further simplifies the payment experience for both consumers and merchants compared to the “scan-and-pay” model ubiquitous in China. Users tap their unlocked phone against a merchant’s terminal or an Alipay Tap! Tag, eliminating the need to open an app, scan a code, or click through multiple screens.
Data from early adopters show the solution also allows merchants to integrate customer engagement tools more seamlessly into the one-tap payment experience. FamilyMart, the nation-wide convenience store chain, reports that membership sign-ups at checkout tripled post-integration.
According to Cyril Han Xinyi, CEO of Ant Group, the company has committed RMB 10 billion to grow the Alipay Tap! ecosystem, empowering partners, especially small businesses to scale.
“From leadership in payment innovation to extensive investments in agentic AI solutions, Alipay is accelerating the two flywheels for its growth: digital payment and 360° digital connectivity,” said Han in a message to Alipay's 80 million merchant partners nation-wide at the 2025 Alipay Tap! Ecosystem Summit. “We believe Alipay Tap! and more similar exciting new initiatives will continue to transform the checkout moment into a wider gateway to enriched consumer experience and merchant business growth.”
The service is also available to international visitors to China, who may now bind their international cards to an Alipay account to pay and travel like a local across the country.
The Alipay Tap! solution now supports over 300 scenarios, including ordering food at restaurants, vending machines, power bank rentals, and customer membership and loyalty programs. Available in more than 400 Chinese cities, Alipay Tap! now serves over 5,000 brands such as Burger King and FamilyMart.
Parallel to the expansion of Tap!, Alipay is also accelerating its investments in AI and its agentic solutions. In March 2025, the company unveiled a comprehensive suite of AI solutions for the healthcare sector. The AI Healthcare Manager in the Alipay app offers access to over 30 services—from doctor recommendations to medical report analysis and personalized advice—and has supported 40 million users since its launch in September 2024.
Earlier in April 2025, Alipay unveiled its Model Context Protocol (MCP) payment server, enabling merchants and developers to use natural language to access Alipay payment services through their preferred MCP clients or AI agents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424690776/en/
Contacts
Media Inquiries
globalcomms@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Legora Attracts $80 Million Series B Funding as Top Global Law Firms and Legal Teams Rush to Adopt Its Collaborative AI21.5.2025 10:00:00 CEST | Press Release
Today, Legora announces an $80 million funding round led by ICONIQ and General Catalyst, with continued support from existing investors Redpoint Ventures, Benchmark, and Y Combinator. This latest round is a strong endorsement of Legora’s product quality, velocity and the remarkable traction it has achieved globally—underscored by its rapid progression from inception to Series B in under two years. The deal comes as adoption of legal AI surges across the world. Legora is at the forefront of this shift - with lawyers across 250 firms and legal teams in 20 markets globally making daily use of its platform to review and research with precision, draft smarter, and collaborate seamlessly. Legora operates out of New York, London, and Stockholm, with 100 employees drawn from some of the world’s leading global law firms and tech companies. Max Junestrand, CEO and founder of Legora said: “The investment is a clear validation of the value our product is delivering to lawyers around the world. Whi
SEKISUI CHEMICAL: Victory in German Patent Infringement Lawsuit Concerning PVB Interlayer Films21.5.2025 10:00:00 CEST | Press Release
The High Performance Plastics Company (President : Akira Asano) of SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Keita Kato; hereinafter “SEKISUI CHEMICAL”) hereby notifies that it has obtained judgments in its favor (hereinafter referred to as “the Judgments”) from the District Court Munich I on April 17, 2025, in the patent infringement litigation (docket No. 7 O 12401/24 and 7 O 12476/24) against Kuraray Europe GmbH (hereinafter referred to as “Kuraray Europe”), a subsidiary of Kuraray Co., Ltd which we previously announced in the press release dated October 16, 2024, titled “Filing of Lawsuit Seeking Injunction and Damages for Patent Infringement in Relation to PVB Interlayer in Germany.” This judgments found that the sound-insulating wedge products manufactured and sold by Kuraray Europe, namely “‘Trosifol’ The Wedge Acoustic” and “‘Trosifol’ The Wedge Acoustic Shadeband” (hereinafter collectively referred to as “Kuraray Products”) infringe European Patent No.
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press Release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press Release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press Release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom